11.66

0.43% 0.05

Pre-market: 11.89 0.23 +1.97%

Korro Bio Inc (KRRO)

Overview News Price History Discussions Forecast

Korro Bio Inc stock is traded at $11.66, with a volume of 244.83K. It is up +0.43% in the last 24 hours and up +14.54% over the past month. Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Previous Close:

$11.61

Open:

$11.83

24h Volume:

244.83K

Relative Volume:

1.48

Market Cap:

$168.17M

Revenue:

$6.39M

Net Income/Loss:

$-117.26M

P/E Ratio:

-0.9342

EPS:

-12.4807

Net Cash Flow:

$-79.08M

1W Performance:

+10.10%

1M Performance:

+14.54%

6M Performance:

+46.48%

1Y Performance:

-13.88%

1-Day Range:

$11.53

$12.51

1-Week Range:

$10.25

$13.07

52-Week Range:

$5.2044

$55.89

Korro Bio Inc Stock (KRRO) Company Profile

Name

Korro Bio Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

617-468-1999

Address

60 FIRST STREET, CAMBRIDGE

Employee

Twitter

Next Earnings Date

2026-05-06

Latest SEC Filings

KRRO's Discussions on Twitter

Compare KRRO vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KRRO Korro Bio Inc	11.66	168.17M	6.39M	-117.26M	-79.08M	-12.48
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Korro Bio Inc Stock (KRRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-13-26	Upgrade	Raymond James	Mkt Perform → Outperform
Feb-17-26	Upgrade	William Blair	Mkt Perform → Outperform
Jan-29-26	Upgrade	Chardan Capital Markets	Neutral → Buy
Jan-29-26	Upgrade	H.C. Wainwright	Neutral → Buy
Jan-29-26	Upgrade	Piper Sandler	Neutral → Overweight
Jan-28-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Jan-28-26	Upgrade	Oppenheimer	Perform → Outperform
Nov-13-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-13-25	Downgrade	Chardan Capital Markets	Buy → Neutral
Nov-13-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-25	Downgrade	Piper Sandler	Overweight → Neutral
Nov-13-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-13-25	Downgrade	Raymond James	Strong Buy → Mkt Perform
Nov-13-25	Downgrade	William Blair	Outperform → Mkt Perform
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Apr-16-25	Initiated	Chardan Capital Markets	Buy
Jan-10-25	Initiated	Oppenheimer	Outperform
Oct-21-24	Initiated	Raymond James	Strong Buy
Aug-14-24	Initiated	William Blair	Outperform
Mar-28-24	Reiterated	H.C. Wainwright	Buy
Feb-27-24	Initiated	BMO Capital Markets	Outperform
Dec-04-23	Initiated	H.C. Wainwright	Buy
Nov-29-23	Initiated	RBC Capital Mkts	Outperform
Nov-10-23	Initiated	Piper Sandler	Overweight
Feb-15-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Feb-13-23	Downgrade	Cowen	Outperform → Market Perform
Sep-22-21	Downgrade	Goldman	Buy → Neutral
Jan-27-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-22-20	Initiated	B. Riley Securities	Buy
Jul-14-20	Initiated	Oppenheimer	Outperform
May-18-20	Downgrade	JP Morgan	Overweight → Neutral
Oct-28-19	Initiated	Cowen	Outperform
Oct-28-19	Initiated	Goldman	Buy
Oct-28-19	Initiated	JP Morgan	Overweight

View All

Korro Bio Inc Stock (KRRO) Latest News

Jun 15, 2026

Korro Bio: RNA Editor Plots Way Back After AATD Study FailI'm Holding (NASDAQ:KRRO) - Seeking Alpha

Jun 15, 2026

Jun 13, 2026

KRRO Q1 2026 Earnings: Narrowed Loss Surprises to the Upside, Shares RallyEarnings Surprise Stocks - newsline.com

Jun 13, 2026

Jun 12, 2026